Paper29972754
Chimeric Antigen Receptor Therapy.
June CH and 1 other. N Engl J Med, 2018. Cited by 1,883 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Chimeric Antigen Receptor Therapy. Papers, record 29972754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29972754
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adoptive Transfer | Major topic |
| Neoplasms | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| Recombinant Fusion Proteins | Major topic |
| T-Lymphocytes | Major topic |
| Antigens, CD19 | |
| Genetic Engineering | |
| Humans | |
| Remission Induction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P01 CA214278 | NCI NIH HHS | United States | P01CA214278 | PubMed |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07390071 | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 29972760 | A Look Forward - The Frontiers in Medicine Series. | https://conductscience.org/library/papers/29972760 |
Source PubMed
References83
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27076371 | Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. | Cancer Discov | 2016 | https://conductscience.org/library/papers/27076371 | PubMed |
| 2 | 26333935 | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/26333935 | PubMed |
| 3 | 26461090 | Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. | Cancer Cell | 2015 | https://conductscience.org/library/papers/26461090 | PubMed |
| 4 | 17855649 | Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17855649 | PubMed |
| 5 | 26516065 | Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. | Cancer Discov | 2015 | https://conductscience.org/library/papers/26516065 | PubMed |
| 6 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 7 | 24597865 | Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24597865 | PubMed |
| 8 | 23247726 | T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. | Blood | 2013 | https://conductscience.org/library/papers/23247726 | PubMed |
| 9 | 26875830 | Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. | Nat Rev Immunol | 2016 | https://conductscience.org/library/papers/26875830 | PubMed |
| 10 | 18688285 | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. | J Clin Invest | 2008 | https://conductscience.org/library/papers/18688285 | PubMed |
| 11 | 24876563 | Current concepts in the diagnosis and management of cytokine release syndrome. | Blood | 2014 | https://conductscience.org/library/papers/24876563 | PubMed |
| 12 | 18026115 | T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. | Nat Med | 2007 | https://conductscience.org/library/papers/18026115 | PubMed |
| 13 | 22553251 | Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22553251 | PubMed |
| 14 | 22935759 | The determination and interpretation of the therapeutic index in drug development. | Nat Rev Drug Discov | 2012 | https://conductscience.org/library/papers/22935759 | PubMed |
| 15 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 16 | 28106152 | Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. | Nat Rev Endocrinol | 2017 | https://conductscience.org/library/papers/28106152 | PubMed |
| 17 | 21830940 | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21830940 | PubMed |
| 18 | 3264384 | Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. | N Engl J Med | 1988 | https://conductscience.org/library/papers/3264384 | PubMed |
| 19 | 24777247 | T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. | Cancer Immunol Res | 2013 | https://conductscience.org/library/papers/24777247 | PubMed |
| 20 | 28029927 | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. | N Engl J Med | 2016 | https://conductscience.org/library/papers/28029927 | PubMed |
Cited by1,374
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,883 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42978867 | Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing. | Front Immunol | 2026 | https://conductscience.org/library/papers/42978867 | PubMed |
| 42973514 | Patient-derived high functional avidity TCR empowers diverse T cell subsets for tumour immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42973514 | PubMed |
| 42963425 | BAZ2A-induced epigenetic states in cancer cells fuel palmitate accumulation in the tumor microenvironment driving CAR-T cell exhaustion. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42963425 | PubMed |
| 42961140 | An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. | Curr Protoc | 2026 | https://conductscience.org/library/papers/42961140 | PubMed |
| 42942996 | Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy. | Nutrients | 2026 | https://conductscience.org/library/papers/42942996 | PubMed |
| 42936601 | CAR-T-cell therapy for autoimmune neurologic diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/42936601 | PubMed |
| 42935498 | Gene therapy as an upcoming technique in the treatment of cancer: A cellular solution to a cellular problem. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42935498 | PubMed |
| 42924291 | Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption. | Med Rev (2021) | 2026 | https://conductscience.org/library/papers/42924291 | PubMed |
| 42909179 | Mapping programmable mRNA research relevant to cancer-associated immune escape: a dual-database bibliometric and topic modeling analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42909179 | PubMed |
| 42905219 | Cardiovascular Toxicity Across the Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42905219 | PubMed |
| 42898905 | Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898905 | PubMed |
| 42898688 | Advances and applications of engineered protein therapeutics and their role in precision medicine. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42898688 | PubMed |
| 42898659 | Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders. | J Orthop Translat | 2026 | https://conductscience.org/library/papers/42898659 | PubMed |
| 42898640 | Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898640 | PubMed |
| 42898508 | An integrative meningioma surfaceome atlas and a transferable framework for CAR-T target nomination. | Front Bioinform | 2026 | https://conductscience.org/library/papers/42898508 | PubMed |
| 42894261 | Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies. | Cancer Sci | 2026 | https://conductscience.org/library/papers/42894261 | PubMed |
| 42890243 | Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42890243 | PubMed |
| 42888448 | CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42888448 | PubMed |
| 42884102 | Bench-to-Bedside Perspectives on the Development of Soluble TCR-Based Protein Biologics: Current Landscape, Control Strategy and Future Direction. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42884102 | PubMed |
| 42881857 | Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881857 | PubMed |
Genes31
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29972754
GET https://conductscience.org/api/papers/v1/29972754/references?page=2